An open repository of community-contributed protocols sponsored by Nature Research.
Learn more about Protocol Exchange
Method Article
Alain Townsend
MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital, Oxford OX3 9DS, UK
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3702-0107
Etienne Joly
Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse; France
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7264-2681
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of
seroconversion in populations, and for seeking evidence for a level of antibody that may be
protective against COVID-19 disease. Several high-performance commercial tests have been
described, but these require centralised laboratory facilities that are comparatively
expensive, and therefore not available universally. Red cell agglutination tests do not
require special equipment, are read by eye, have short development times, low cost and can
be applied at the Point of Care. We describe a quantitative Haemagglutination test (HAT) for
the detection of antibodies to the receptor binding domain of the SARS-CoV-2 spike protein.
The HAT has a sensitivity of 90% and specificity of 99% for detection of antibodies after a
PCR diagnosed infection. We will supply aliquots of the test reagent sufficient for ten
thousand test wells free of charge to qualified research groups anywhere in the world.
Keywords
hemagglutination. serodiagnostic
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 26 May, 2021
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Associated Publications
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
by Alain Townsend, Pramila Rijal, Julie Xiao, +60
Nature Communications (29 March, 2021)
An open repository of community-contributed protocols sponsored by Nature Research.
Learn more about Protocol Exchange
Method Article
Alain Townsend
MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital, Oxford OX3 9DS, UK
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3702-0107
Etienne Joly
Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse; France
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7264-2681
Version History
CURRENT STATUS: Posted
Version 1
Posted 26 May, 2021
No community comments so far
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of
seroconversion in populations, and for seeking evidence for a level of antibody that may be
protective against COVID-19 disease. Several high-performance commercial tests have been
described, but these require centralised laboratory facilities that are comparatively
expensive, and therefore not available universally. Red cell agglutination tests do not
require special equipment, are read by eye, have short development times, low cost and can
be applied at the Point of Care. We describe a quantitative Haemagglutination test (HAT) for
the detection of antibodies to the receptor binding domain of the SARS-CoV-2 spike protein.
The HAT has a sensitivity of 90% and specificity of 99% for detection of antibodies after a
PCR diagnosed infection. We will supply aliquots of the test reagent sufficient for ten
thousand test wells free of charge to qualified research groups anywhere in the world.
Loading...
Associated Publications
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
by Alain Townsend, Pramila Rijal, Julie Xiao, +60
Nature Communications (29 March, 2021)